Literature DB >> 5073299

Protocol for an evaluative study of the protective effect of isolation systems and decontamination in patients with high susceptibility to infection.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5073299     DOI： 10.1016/0014-2964(72)90118-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  5 in total

1.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results.

Authors:  M Dietrich; W Gaus; J Vossen; D van der Waaij; F Wendt
Journal:  Infection       Date:  1977       Impact factor: 3.553

2.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. II. Organizational and statistical concept.

Authors:  W Gaus; F Wendt; G Wolf
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Clinical use of reverse isolation in a protected environment.

Authors:  M Bláha; J Vanásek; V Mĕrka; M Splino; J Malý; O Siroký
Journal:  Folia Microbiol (Praha)       Date:  1979       Impact factor: 2.099

4.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukaemia patients. III: The quality of isolation and decontamination.

Authors:  J Dankert; W Gaus; H Gaya; D Krieger; G Linzenmeier; D van der Waaij
Journal:  Infection       Date:  1978       Impact factor: 3.553

5.  Infection by the distribution of biotypes of enterobacteriacease species in leukaemic patients treated under ward conditions and in units for protective isolation in seven hospitals in Europe.

Authors:  D Van der Waaij; T M Tielemans-Speltie; A M De Roeck-Houben
Journal:  Infection       Date:  1977       Impact factor: 3.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.